Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Institutional Investors Approve of SEC’s Shareholder Proxy Changes

Price is not the point? You do understand that it costs them money to purchase stock with out of the money options, don't you. It is NOT additional compensation. The only possible advantage they get by purchasing these options, rather than over the counter, is that they get a block purchase at one price instead having the risk of the price going higher because this stock is thinly traded. Certainly a point not even worth discussing as any "advantage" is pure speculation as to amount.

Better think that one thru again, Stan.

Share
New Message
Please login to post a reply